

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Shimada, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/010377

Title: Fused Azole-Pyrimidine Derivatives

**MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

**FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

  
\_\_\_\_\_  
William F. Gray  
Reg. No.: 31,018  
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
Telephone: (203) 812-2712  
Facsimile: (203) 812-6459

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No.	Art Unit	Filing Date	Atty. Docket No. RCK-36
INFORMATION DISCLOSURE CITATION		Applicant(s) SHIMADA, et al.			
		10/527376			

## U.S. PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	U1	3	6	4	4	3	5	4	02/22/72	Hardtmann	260	247.5	09/16/68

## FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

F1	Ui, M., et al., "Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase", TIBS, 20(8): 303-307 (August 1995)
F2	Vlahos, C. J., et al., "A Specific Inhibitor of Phosphatidylinositol 3-Kinase, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)", J. Biol. Chem., 269(7): 5241-5248 (February 1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.